Objective: Comparison of new bone formation in maxillary sinus augmentation procedures by using biomaterial associated with mesenchymal stem cells (MSCs) separated by two different isolation methods.
INTRODUCTION
Preclinical and clinical studies have demonstrated the ability of bone marrow derived stem and progenitor cells to regenerate many tissues, including bone. 1, 2 Current literature in various fields of medicine shows the benefit of using a cocktail of mononuclear cells (MNCs) without expanding them in vitro prior to reimplantation.
Hernigou et al have demonstrated the healing of tiba non-unions with grafting of autogenous marrow cells. 3 Esato et al showed the advantage of injecting MNCs from bone marrow into peripheral arterial disease, leading to neovascularisation around the injection sites. 4 In the field of maxillofacial bone grafting Smiler et al. have shown that the use of bone marrow derived mesenchymal stem cells (MSCs) is feasible. But they did not concentrate the cells. 5 Soltan et al. suggest that the use of bone marrow aspirate which contains adult stem cells may become a new "platinum standard". 6 These new techniques of tissue engineering for bone reconstruction may emerge as an alternative to conventional grafts. Harvesting of MSCs involves little donor site surgery, whereas autogenous bone harvesting is costly and associated with certain morbidity. It also requires general anaesthesia and hospitalization. 7, 8 The minimal invasiveness of bone marrow aspiration may give the possibility to save the regenerative advantages of autologous bone grafting but eliminates general anaesthesia, hospitalisation and patient's morbidity.
The REPAIR-AMI and ASTAMI trials showed differences in contractile recovery of left ventricular function after infusion of bone marrow-derived cells in acute myocardial infarction. [9] [10] [11] These outcomes evoked a discussion about the effect of different MNC possessing methods. 12 A better understanding of the mode of action is required to optimize tissue-engineering procedures for clinical applications. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
As most of the previous clinical trials involved bone marrow derived MNCs isolation by FICOLL, this technique is currently viewed as the gold standard. 9, 10, 15 The FICOLL method can be an effective procedure for MNC-concentration that may be useful mainly in hospitals. Thus, the limitations of the FICOLL-method are the time needed for its procedure and that a good manufacturing practice (GMP) laboratory is required. Closed systems are therefore necessary for the clinical use in operating facilities without GMP possibilities. 16, 17 To evaluate if the open FICOLL-method can be substituted by a closed system the new bone formation resulting from transplanted MNCs was compared in patients who received cells either concentrated by the FICOLL-method or by the closed BMAC-system.
Materials and Methods

Study Population and Protocol
The protocol was approved by the ethics committee of the University of Freiburg, and the study was conducted in accordance with the Declaration of Helsinki.
Patients older than 18 years with need of dental implant placement in the posterior maxilla were eligible for the study if they had a maximum of 3 mm residual height of the alveolar ridge. In addition they had to be able to comply with study related procedures as for example returning for follow-up examinations, exercising good oral hygiene and being able to understand the nature of the proposed surgery. Informed consent was obtained prior to surgery. Exclusion criteria were smoking, history of malignancy, radiotherapy or chemotherapy, pregnancy or nursing, general contraindications for dental or surgical treatment, medication, treatment or disease, which may have an effect on bone turnover, bone or connective tissue metabolism and allergy to collagen.
Six sinus from four patients at an average age of 59.5 years (range, 50 to 69 years)
were comprised in the FICOLL-group. Twelve sinus from seven patients at an average age of 55 years (range 47 to 68 years) were included in the BMAC-group.
There were more sinus in the BMAC-group because later the FICOLL-method was completely replaced by the BMAC-system. A total of 50 implants were placed in a second surgical intervention (17 FICOLL / 33 BMAC). Implant survival was evaluated after 1 year.
Harvesting of Stem Cells
The pelvic bone was punctured about 2cm laterocaudally from the superior posterior iliac spine with a bone marrow biopsy needle. With three 20 ml syringes (B.
Braun, Melsungen, Germany) each containing 0.3 ml of heparin solution (HeparinNatrium, 10.000 U/ml, diluted with NaCl to 1000 U/ml, both B. Braun, Melsungen, Germany) 60 ml of bone marrow were collected. The aspirate was pooled and anticoaguluated with 5 ml of heparin solution (Heparin-Natrium, 10.000 U/ml, diluted with NaCl to 1000 U/ml, both B. Braun, Melsungen, Germany). The bone marrow aspirate was given to the laboratory to separate the mononucleated cells with the FICOLL-method. According to the instructions of the manufacturer bone marrow cells were isolated directly in the operating room by using the BMAC system (Bone 
Proof of Pluripotency
The cells from the bone marrow concentrate were amplified and differentiated into three cell lineages according to the methods of Pittenger and coworkers. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Histological Evaluation
The burrs with the bone biopsies were fixed in formalin for 48 hours, rinsed in water 
Statistical Analysis
For the parameters NewBone (new bone formation), BioOss (Biomaterial) and Marrows (marrow space) value were expressed in % of the evaluated area. A linear mixed mode (lme of package nlme. under R) was used for analysis; 90% confidence intervals were computed from the contrast tables of the model. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
RESULTS
All patients participated through the end of the study. No patient dropped out. All patients recovered well from the surgical procedure. Postoperatively there were no complaints about pain, haematoma or infection at any time after bone marrow aspiration and sinus floor augmentation.
Healing Time
Average healing time was (143 ± 39 days) for group FICOLL and (112 ± 17 days) for BMAC. The difference was not statistically significant (p = 0.22).
Histological analysis
Histological specimens of both FICOLL and BMAC showed similar results. The histological sections showed no signs of inflammation. The newly formed osseous lamellae appeared as vital bone tissue containing osteocytes inside the bone lacunae. In comparison to lamellar bone the biomaterial could be easily identified by its size, shape and color. In the Azur II Pararosanilin staining the newly formed bone appeared in a darker red than the BBM particles. The newly formed bone lamellae connected the biomaterial particles and stabilized the grafted complex. Bone formation appeared in the macro pores of the biomaterial as well. Blood vessels could be detected in the biopsy. The biomaterial with the newly formed bone was integrated well in the surrounding host bone (Fig 1) .
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Histomorphometric analysis
An overview of the estimated values and the 90%-confidence intervals of new bone formation, biomaterial and marrow space are displayed in figure 2 . The values for each histological slide are given in table 1.
New bone formation
The estimated value of new bone formation for FICOLL, measured in percent, was 15.5%, with a 90%-confidence interval from 8.6% to 22.4% (Fig. XX, Tab. 1 ). This means that for FICOLL with 5% probability the expected value is lower than 8.6%
and with 5%-probability it is higher than 22.4%. The estimated value of BMAC is 19.9%, with a 90%-confidence interval from 10.9% to 29%. The estimated value of the difference in new bone formation between BMAC and FICOLL, the reference, was 4.4%. The 90%-confidence interval of the difference ranged from -4.6% to 13.5%.
With 5% probability the expected difference of new bone formation between BMAC and FICOLL is therefore lower than -4.6% and with a 5% probability higher than This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
FICOLL is 12.2%, with a 90%-confidence interval from 4.32% to 20%. This means that with a 5% probability the expected Biomaterial difference between BMAC-FICOLL is lower than 4.32% and with a 5% probability it is higher than 20 %. Both limits of the confidence interval for the difference are positive, so biomaterial is significantly higher for BMAC (p = 0.019). In other words: with 95% probability, biomaterial is higher for BMAC by at least 4.32 percentage points.
Marrow space
The estimated value of marrow space for FICOLL, measured in percent, is 64.8 %,
with a 90%-confidence interval from 57.1% to 72.5%. The estimated value of the marrow space in the BMAC-group was 64.8 % + (-17.4 %) = 47.4 %, with a 90%-confidence interval from 37.6 % to 57.3 %. The estimated value of the difference in marrow space between BMAC and the reference FICOLL is -17.4 %, with a 90%-confidence interval from -27.2 % to -7.48 %. This means that with 5% probability the expected difference of the marrow space between the BMAC-and the FICOLL-group is lower than -27.2 % and with 5% probability it is higher than -7.48 %. Both limits of the confidence interval for the difference are negative, so marrow space is significantly lower for BMAC (p = 0.01). With 95% probability, marrow space is lower for BMAC by at least 7.48 percentage points.
Colony Forming Unit Assay (CFU)
The number of CFUs did not differ significantly. There were 28.7 (±14.1) CFUs/1x10 
Proof of Pluripotency
The cultured mesenchymal stem cells could be differentiated successfully into (Fig. 3) .
Follow-up and Implant Survival
Although no implant out of 17 was lost in the FICOLL group, only one implant out of 33 failed in the BMAC group before prosthetic loading. No implant was lost after loading. All 49 osseointegrated implants were loaded and in function. Up to now, all patients were subject to follow-up examinations 2 years after implant placement.
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DISCUSSION
In the present study the bone forming ability of cells isolated with a point-of-care device for bone marrow aspirate (BMA) was assessed in comparison to bone marrow cells isolated by FICOLL. This in-vivo study was carried out in humans for two reasons. One was to find out if the procedures enable bone growth in the maxillary sinus to facilitate dental implant insertion. The other reason was to see whether results from animal trials with FICOLL can correlate to the outcome in humans when the BMAC-device is used.
21
Sinus floor grafting is considered to be successful, if dental implants can be placed into a posterior maxilla which had originally an insufficient bone height and if the implants are stable over time. The one implant lost in the BMAC-group is of no significance as it is within the normal loss rate. 22 There are some advantages of autogenous bone for sinus augmentation. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 26 The new bone formation in the present study is higher when compared to histomorphometrical analysis of sinuses augmented purely with BBM. 24 The here presented data also support the data of Hernandez-Alfaro, who found accelerated bone formation rates induced by autologous bone-marrow cells in a clinical feasibility study, by using an ex vivo cultured and autologous bone marrowderived cell product. 28 Comparison took place within a randomized investigation in humans undergoing a bilateral sinus augmentation by either using BBM alone or in combination with the so-called "Tissue repair cells" ("TRC", Astronom Biosciences, This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
tricalciumphosphate/hydroxyapatite scaffolds which were vitalized with cultured mesenchymal stem cells. 29 Although the bone marrow cell processing method differs from the one used in the present investigation, it could be stated that the method is feasible and that bone marrow derived cells in maxilliary sinus augmented with BBM seem to support bone formation.
Hermann et al. found 2.4 times more nucleated cells with BMAC when comparing cells of 25 patients processed with the BMAC-or the FICOLL-method in vitro. (16) The same group showed in an ischemic limb rodent model that the BMAC-group underwent faster regeneration than the FICOLL-group. 16 This might be also because both separation methods result in specifically different cell products. In a FICOLL preparation 80% to 90% of the cells present are mononuclear, a maximum of 5% are granulocytes, a maximum of 10% are erythrocytes and <0.5% are thrombocytes. The cells are usually suspended in NaCl-solution. The BMAC product is suspended in autologous plasma and contains a maximum of 54% granulocytes, a maximum of 34% mononuclear cell and 17% erythrocytes. The fact that the cells are not removed from their natural plasma environment may help to sustain the functionality of the cells. 16 Another in vivo comparison of two different BMA-processing methods (FICOLL vs. Lymphoprep) was investigated in a murine model of hindlimb ischaemia by Seeger and co-workers. 12 They concluded that cell isolation protocols have a major impact on the functional activity of bone marrowderived progenitor cells and that the assessment of cell number and viability may not entirely reflect the functional capacity of cells in vivo.
Karsten et al. compared the FICOLL-method in vitro with two BMA processing methods which use the closed SEPAX-system (Biosaye, Eysins, Switzerland). 30 Compared to FICOLL they found significantly higher numbers of CFUs in the SEPAXvolume-reduction-group followed by the SEPAX-FICOLL-group. As in the present study there were no significant differences in the differentiation abilities of the cells.
Sakai et al. introduced a simple centrifugal BMA processing method with a blood bag system which could be potentially operated "chair side". In 10 patients they found a 5-fold increase of nucleated and colony forming cells. (31) The system has not been compared to others. With BMA of 12 patients Horn et al. showed in vitro that red blood cell (RBC) -lyses with ammonium chloride could provide a more effective alternative to the FICOLL-method. The RBC-lyses was faster, resulted in larger colonies (CFU-assay) and showed no differences in phenotype and differentiation potential.
32
The FICOLL-method is an open system. The aspirate has to leave the operating facility to be processed. This is costly and transfusion regulations apply if the method is not used in an experimental setting. A practical clinical approach therefore requires a closed system which can be operated chair-side and do not require GMP facilities.
The SEPAX-system is approved for the processing of umbilical cord blood. The
Harvest BMAC-system has the advantage that it is approved for the processing of BMA for hard tissue regeneration.
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